Biotech | May 09, 2022
SCG Cell Therapy announces HSA clinical trial approval of TCR-T cell therapy for liver cancer
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation (RAS)
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
Center of Excellence for Molecular Diagnostics and Proteomics will enable affordable diagnostics for infectious diseases in India
The plant is expected to start commercial operations from Q4FY24
The management believes that its strong product pipeline, diversified innovative product portfolio, continued expansion into new geographies and FGMP accreditations will help sustain the growth momentum in the coming few years
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Beyond the technical leadership from F1, the collaboration will bring a specific focus on the people dimension of high performance
Subscribe To Our Newsletter & Stay Updated
